Taruno Kanae, Den Hiroki, Takeuchi Mieko, Inuzuka Mayuko, Arai Masami, Nakamura Seigo, Ishida Takanori
Division of Breast Surgical Oncology, Department of Surgery, Showa Medical University School of Medicine, Tokyo, Japan.
Department of Hygiene, Public Health, and Preventative Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Breast Cancer Res Treat. 2025 Sep 6. doi: 10.1007/s10549-025-07815-2.
This large-scale study presents the clinicopathological characteristics and cumulative incidence of contralateral breast cancer (CBC) in Japanese BRCA1/2 pathogenic variant carriers, including cases diagnosed after the implementation of national insurance coverage.
We analyzed 2949 breast cancer cases from the registry database of the Japanese Organization of Hereditary Breast and Ovarian Cancer.
BRCA1 carriers predominantly developed triple-negative breast cancer, whereas BRCA2 carriers more frequently developed luminal-type tumors, with a younger age of onset observed in BRCA1 carriers. No significant clinicopathological differences were found between the age groups. The cumulative incidence of CBC was 10.0% at five years and 29.0% at 10 years among BRCA1 carriers and 14.0% at five years and 19.0% at 10 years among BRCA2 carriers. CBC was observed in all age groups, including older patients. These findings highlight the importance of individualized decision-making in surgical planning and surveillance strategies.
This study included a broad age range of patients, reflecting real-world data following the expansion of insurance coverage in Japan. Further case studies and long-term follow-up are warranted. Our findings support the development of appropriate clinical care and preventive strategies for BRCA1/2 carriers in Japan.
本大规模研究呈现了日本BRCA1/2致病变异携带者对侧乳腺癌(CBC)的临床病理特征和累积发病率,包括在国家保险覆盖实施后诊断的病例。
我们分析了日本遗传性乳腺癌和卵巢癌组织登记数据库中的2949例乳腺癌病例。
BRCA1携带者主要发生三阴性乳腺癌,而BRCA2携带者更常发生管腔型肿瘤,BRCA1携带者发病年龄更年轻。各年龄组之间未发现显著的临床病理差异。BRCA1携带者中CBC的累积发病率在5年时为10.0%,10年时为29.0%;BRCA2携带者中CBC的累积发病率在5年时为14.0%,10年时为19.0%。在所有年龄组中都观察到了CBC,包括老年患者。这些发现突出了手术规划和监测策略中个体化决策的重要性。
本研究纳入了广泛年龄范围的患者,反映了日本保险覆盖范围扩大后的真实世界数据。有必要进行进一步的病例研究和长期随访。我们的研究结果支持为日本的BRCA1/2携带者制定适当的临床护理和预防策略。